Nuvectis Pharma, Inc.
NVCT Nasdaq
SEC CIK 1875558
Follow Nuvectis Pharma
Weekly email: filings, results
Net income
−$30.1M
−303% vs same quarter last year
EPS, diluted
−$1.02
−131.8% vs same quarter last year
Operating cash flow
−$25.3M
−462.5% vs same quarter last year
Operating income
−$31M
−298.4% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$26.4M |
| FY24 | −$19M |
| FY23 | −$22.3M |
| FY22 | −$19.1M |
| FY21 | −$12.9M |
| FY20 | - |